TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?-Reference-Cited by-同舟云学术

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?

Published:2023-04 Issue:4 Volume:7 Page:e855
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Bomben Riccardo¹,Zucchetto Antonella¹,Pozzo Federico¹,Tissino Erika¹,Bittolo Tamara¹,Olivieri Jacopo²,Chiarenza Annalisa³,Zaja Francesco⁴,Del Principe Maria Ilaria⁵,Rossi Davide⁶⁷,Gattei Valter¹

Affiliation:

1. Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy

2. Clinica Ematologica, Centro Trapianti e Terapie Cellulari “Carlo Melzi” DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy

3. Division of Haematology, Ferrarotto Hospital, Catania, Italy

4. Department of Medical, Surgical and Health Sciences, University of Trieste, Italy

5. Division of Haematology, University of Tor Vergata, Rome, Italy

6. Haematology, Institute of Oncology Research, Bellinzona, Switzerland

7. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Publisher

Wiley

Subject

Hematology

Reference9 articles.

1. Five percent variant allele frequency is a reliable reporting threshold for TP53 variants detected by next generation sequencing in chronic lymphocytic leukemia in the clinical setting.;Pandzic;HemaSphere,2022

2. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia - update on methodological approaches and results interpretation.;Malcikova;Leukemia,2018

3. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.;Rossi;Blood,2014

4. Clinical outcomes in patients with multi-hit TP53 chronic lymphocytic leukemia treated with ibrutinib.;Brieghel;Clin Cancer Res,2021

5. Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.;Malcikova;Blood,2021